Peregrine Pharmaceuticals to Present at Rodman & Renshaw 8th Annual Healthcare Conference

- Presentation to Be Webcast Live and Archived on Company's Website -

TUSTIN, Calif., Nov. 2 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a biopharmaceutical company developing targeted therapeutics for the treatment of hepatitis C virus (HCV) infection and cancer, today announced that senior management will present at the Rodman & Renshaw 8th Annual Healthcare Conference on Wednesday, November 8, 2006 at 9:55 am EST. The presentation will be held at the New York Palace Hotel in New York City.

Peregrine CEO and president Steven W. King will provide a review of recent corporate developments.

Mr. King's presentation will be webcast live and can be accessed by visiting the Investor Relations section of Peregrine's website at www.peregrineinc.com. A replay will be available on the Peregrine website and archived for approximately 30 days.

For more information about this conference, please visit: http://www.rodmanandrenshaw.com/Conferences.asp?CID=conf19

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing five separate clinical trials in cancer and HCV infection with its lead product candidates bavituximab and Cotara® in the U.S. and India. Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

    Contacts:
    GendeLLindheim BioCom Partners
    Investors                                       Media
    info@peregrineinc.com                           Barbara Lindheim
    (800) 987-8256                                  (212) 918-4650

SOURCE Peregrine Pharmaceuticals, Inc.
11/02/2006

CONTACT: Investors, +1-800-987-8256, info@peregrineinc.com, or Media,
Barbara Lindheim, +1-212-918-4650, both of GendeLLindheim BioCom Partners, for
Peregrine Pharmaceuticals, Inc.
Web site: http://www.avidbio.com
Web site: http://www.peregrineinc.com
(PPHM)